Funding Pathways for Biotech small businesses
By Staff Reporter, 17 March 2026.
It is undeniable that South Africa has created a powerful, multi-channel funding ecosystem for biotechnology and health‑innovation Micro, Small, and Medium Enterprises (MSMEs). The environment blends bioeconomy‑specific grants, manufacturing incentives, and MSME‑focused blended finance, which builds real openings for agile companies that can commercialise science, build local manufacturing capacity, or solve challenges related to the health system.
For early‑stage and scaling biotech ventures, below we list the most relevant, accessible, and strategically aligned funding channels that may be explored.
1. Bioindustries Funding Call (TIHMC + DSI)
According to MSME Africa, this is a dedicated national programme supporting startups in the bioeconomy, offering R51,000–R300,000 per year for product development, prototyping, and early commercialisation. It targets ventures in biomanufacturing, biocatalysis, bioremediation, microbial bioprospecting, and biorefineries.
This is a significant programme for MSMEs because it was designed specifically for early‑stage biotech innovators and it includes incubation, mentorship, and technical support. Its importance is fortified by the fact that it fills the “proof‑of‑concept to prototype” funding gap that used to be a big issue for entrepreneurs.
The programme is best suited for synthetic biology, diagnostics, biomaterials, environmental biotech, fermentation‑based products.
2. Manufacturing Support Programme (MSP)
According to the Department of Trade, Industry and Competition, the Manufacturing Support Programme (MSP) is a major incentive scheme supporting manufacturing competitiveness, including pharmaceuticals, chemicals, and green industries. The programme offers capital investment grants, green‑tech grants, quality standards and related skills development, and working capital loans up to R10 million.
The role played by MSP in the biotech space cannot be overstated as it supports Good Manufacturing Practice (GMP) facility upgrades, funds equipment for lab‑to‑manufacturing scale‑up, and enables local production of biologics, diagnostics, and medical consumables.
Categories such as biomanufacturing, medical devices, diagnostics production, pharmaceutical formulation are targeted for support.
3. MSMEs and Co-operatives Funding Policy
According to the Department of Small Business Development (DSBD), the Funding Policy is principally a national framework designed to expand access to finance for MSMEs and co-operatives through various development finance instruments such as blended finance, improved credit infrastructure, and coordinated support across government. The Funding Policy addresses early‑stage financing, working capital, and enterprise development barriers.
This is a game changing instrument because it opens pathways for biotech MSMEs to access blended finance, strengthens credit infrastructure for high‑risk, high‑innovation sectors, and supports cooperatives in community‑based health and biotech initiatives. This intervention is timely considering the need for coordination in the provision of targeted funding in the MSME ecosystem.
MSMEs that run digital health platforms, community diagnostics, biotech cooperatives, health‑tech are best placed to access funding coordinated through this progressive policy.
Biggest opportunities for Biotech MSMEs
Biotech is capital‑intensive, but MSMEs can win by focusing on niche, high‑value segments that don’t require massive infrastructure upfront.
1. Contract research and lab services
MSMEs can offer molecular testing, bioinformatics analysis, cell culture services, and environmental biotech testing.
These services plug into universities, hospitals, and private Research & Development.
2. Diagnostic innovation
There is strong demand for rapid tests for TB, HIV, STIs, diabetes; point‑of‑care diagnostics for rural areas; and AI‑enabled pathology tools.
MSMEs can partner with public health programmes and private labs.
3. Biomanufacturing micro facilities
There is a good opportunity for small‑scale facilities to produce enzymes, reagents, microbial products, and biomaterials.
Equipment and compliance upgrades can be financed through MSP and bioindustry grants.
4. Health tech and digital platforms
Opportunities in this area include, among others; telehealth, remote monitoring, clinical decision‑support tools, and community health worker platforms. These low‑infrastructure and high‑impact opportunities are in sync with the funding principles envisaged in the DSBD’s MSME funding policy.
5. Environmental and industrial biotech
These areas have big potential to scale and include waste‑to‑value bioprocesses, bioremediation, industrial biocatalysis, and circular bioeconomy products. Significantly, align strongly with the priority themes of the Bioindustries Funding Call.
How can MSMEs position themselves to receive funding?
Always consider that funding bodies look for innovation, feasibility, and economic impact. Therefore, it is prudent for MSMEs should focus on the following:
- Problem definition: reflect the health or industrial gap you’re solving.
- Proof of concept: even small lab results or prototypes strengthen applications.
- Market demand: demonstrate demand from clinics, labs, or industry partners.
- Business model: show how you will scale beyond grant funding.
- Job creation: show the business’ potential to create job opportunities.
- Partnerships: with credible institutions add positive weight.
It is advisable that entrepreneurs link up with professionals to assist them to structure proposals, develop financial models, and align ventures with the right funding channels.
In summary
The funding pathways and business opportunities mentioned here are opening space for agile African innovators, especially those who can bridge community health needs with global biotech trends. The available support for healthcare and biotechnology is active, multi‑layered, and expanding, with funding, policy frameworks, and national strategies designed to grow the sector and close critical gaps. These pathways and opportunities demonstrate that there is a commitment to strengthen research, innovation, and the broader bioeconomy.
Over to you, MSMEs!